申请人:Seldar Pharma Inc.
公开号:US10016410B2
公开(公告)日:2018-07-10
To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
提供一种药物,特别是一种可用作肠易激综合征(IBS)治疗剂的化合物。研究发现,一种在 4 位具有酰胺基团的四氢异喹啉-1-酮衍生物或其药学上可接受的盐具有很好的蚕豆素 2(BB2)受体拮抗作用。研究还发现,四氢异喹啉-1-酮衍生物对肠道运动障碍也有很好的疗效。综上所述,本发明的四氢异喹啉-1-酮衍生物可作为一种治疗剂,用于治疗与 BB2 受体相关的疾病,特别是肠易激综合征。